What is Elucidata?
Founded in 2015 and headquartered in Cambridge, Massachusetts, Elucidata specializes in transforming raw biomedical data into actionable insights. At the core of its operations is the Polly platform, a comprehensive ecosystem designed to streamline data storage, transfer, and file access. By providing advanced screening data capabilities, Elucidata addresses the critical bottlenecks in drug discovery and clinical research. The company serves as a vital bridge between high-throughput biological data and the researchers who require precision analytics to drive innovation in healthcare and biotechnology.
How much funding has Elucidata raised?
Elucidata has raised a total of $21M across 2 funding rounds:
Other Financing Round
$5M
Series A
$16M
Other Financing Round (2021): $5M with participation from IvyCap Ventures and Hyperplane Venture Capital
Series A (2022): $16M led by Hyperplane Venture Capital, Eight Roads, IvyCap Ventures, and F-Prime Capital Partners
Key Investors in Elucidata
Hyperplane Venture Capital
A seed-stage firm based in Boston that partners with founders harnessing machine intelligence and cloud computing to solve complex problems at the nexus of perception and insight.
IvyCap Ventures
A firm dedicated to supporting entrepreneurs from premier educational institutions, focusing on early to growth-stage startups across sectors like DeepTech and HealthTech.
F-Prime Capital Partners
A Massachusetts-based investment firm comprised of engineers, doctors, and scientists dedicated to funding innovation within the healthcare and technology sectors.
What's next for Elucidata?
With this latest capital injection, Elucidata is well-positioned to scale its enterprise-level operations and enhance the feature set of the Polly platform. The strategic focus will likely center on deepening its integration within the global pharmaceutical R&D pipeline, where the need for standardized, accessible, and high-quality data is paramount. As the company matures, it is expected to leverage its strong investor backing to expand its footprint in the competitive healthtech landscape, potentially exploring new verticals in precision medicine and automated laboratory workflows. The firm remains committed to its mission of democratizing data access for scientists, ensuring that the next generation of therapeutic breakthroughs is supported by robust, cloud-native infrastructure.
See full Elucidata company page
